Novartis Says European Commission Approved Cosentyx for Polymyalgia Rheumatica Treatment

MT Newswires Live10-21 23:36

Novartis (NVS) said Wednesday that the European Commission has approved Cosentyx for the treatment of adults with polymyalgia rheumatica, a common inflammatory rheumatic disease, characterized by acute pain and stiffness in the shoulders, neck, and hips.

The recommended dose for Cosentyx is 150 mg by subcutaneous injection with initial dosing at weeks zero to four, followed by monthly maintenance dosing in combination with a tapering course of glucocorticoids, Novartis said.

Additional regulatory reviews of Cosentyx in polymyalgia rheumatica are ongoing in US and Japan, Novartis further said.

Price: 153.54, Change: -0.10, Percent Change: -0.06

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment